Navigation Links
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins

LEIDEN, The Netherlands, and PARSIPPANY, N.J., Feb. 10 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6(R) cell line located in the European Union.

Karen King, president of DSM Biologics notes, "The growing number of PER.C6(R) licensees requires that we expand the possibilities for our licensees to obtain services like cell line generation. We are confident that Bioceros' excellent experience and service level will provide our European licensees additional options to move their PER.C6(R) programs forward successfully."

Bram Bout, CEO of Bioceros added, "We are honored to achieve the distinction of being the first pre-approved Europe-based cell line generation partner using the PER.C6(R) cell line. The PER.C6(R) technology is recognized throughout our industry as providing important advantages compared to other platforms, including its well developed technology, which allow for short manufacturing timelines and exceptionally high productivity levels with off the shelf available culture media. The selection of Bioceros as a preferred Vendor by DSM and Crucell underscores the high quality of the services that we offer to our customers."

The PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(R) human cell line and DSM's proprietary XD(TM) technology, a record yield of over 27 grams per liter in the production of IgG antibodies has been achieved.

Other terms of the agreement were not disclosed.

PER.C6(R) technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

XD(TM) technology

DSM's XD(TM) technology has been developed as a proprietary system to drive yield improvements in mammalian systems. "XD" stands for extreme density, as the process is able to push the cell density within the bioreactor to maximum productivity.

Bioceros B.V.

Bioceros is a biotech company focusing on pre-clinical development of protein products, with an emphasis on monoclonal antibodies. Bioceros has a technology platform, consisting of generation of high protein producing mammalian cell lines, process development and pre-clinical manufacturing at 20L scale in disposable bioreactors. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. In addition, Bioceros has vast experience in pre-clinical development of monoclonal antibodies, including proof of concept and toxicology studies in animals. Bioceros uses this technology platform to offer services to the industry and academia, and to develop its own pipeline of monoclonal antibody products.

Bioceros is located in Utrecht, the Netherlands. For more information, please visit


Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6(R) production technology. The Company licenses its PER.C6(R) technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, Sanofi-Aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over 1000 people. For more information, please visit

DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6(R) human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combination of the PER.C6(R) human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. More information:

Royal DSM N.V. - The Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information:

DSM Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release. Crucell N.V. has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell N.V. with the U.S. Securities and Exchange Commission on May 7, 2008, and in particular the section entitled "Risk Factors". Crucell N.V. prepares its financial statements under International Financial Reporting Standards (IFRS).

For further information please contact:

    DSM Pharmaceutical Products     Crucell N.V.
    Karen King                      Oya Yavuz
    President                       Director Corporate Communications &
    DSM Biologics                   Investor Relations
    Tel: +1-973-257-8427            Tel: +31-71-519 7064    

    DSM Biologics                   Bioceros B.V.
    Jeremy Caudill                  Bram Bout
    Vice President                  CEO
    Marketing, Sales & NBD          Tel: +31-30-253 7910
    Tel: +1-415-643-2213  

SOURCE DSM Biologics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
2. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
5. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
6. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
7. ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City
8. Sigma-Aldrich Signs Agreement With CPC Scientific for the Distribution of PEPscreen(R) Custom Peptide Libraries
9. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
10. University of Helsinki and ASM International renew research agreement on atomic layer deposition
11. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
Post Your Comments:
(Date:11/24/2015)... York , November 24, 2015 ... a recent market research report released by Transparency Market ... to expand at a CAGR of 17.5% during the ... Prenatal Testing Market - Global Industry Analysis, Size, Volume, ... the global non-invasive prenatal testing market to reach a ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... InSphero AG, ... 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... Aregger served on the management team and was promoted to Head of ...
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/23/2015)... 2015   Ceres, Inc . (Nasdaq: CERE ... for the fiscal year ended August 31, 2015 and ... --> --> During fiscal year 2015, ... products with a better balance of yield, energy and ... with several leading crop input providers and made significant ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):